Xilio Therapeutics, Inc. (XLO)
- Previous Close
1.0500 - Open
1.0500 - Bid 0.8777 x 100
- Ask 0.9310 x 100
- Day's Range
0.8366 - 1.1097 - 52 Week Range
0.4900 - 3.2500 - Volume
632,105 - Avg. Volume
1,266,368 - Market Cap (intraday)
33.86M - Beta (5Y Monthly) -0.09
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5700 - Earnings Date Apr 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.50
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
xiliotx.comRecent News: XLO
Performance Overview: XLO
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XLO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XLO
Valuation Measures
Market Cap
33.86M
Enterprise Value
8.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.50
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-49.44%
Return on Equity (ttm)
-107.25%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-76.4M
Diluted EPS (ttm)
-2.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
44.7M
Total Debt/Equity (mrq)
34.08%
Levered Free Cash Flow (ttm)
-42.32M